|
Second-line avelumab treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from a global expanded access program (EAP). |
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Novartis; Roche |
Research Funding - Bristol-Myers Squibb; Roche |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche |
| |
|
Honoraria - Amgen; Bristol-Myers Squibb; Merck |
Consulting or Advisory Role - Amgen |
Speakers' Bureau - Bristol-Myers Squibb; Merck |
| |
|
Honoraria - Bayer; Eisai; Lilly; Novartis; Pfizer; PharmaMar |
Consulting or Advisory Role - Bayer; Eisai; Lilly; Novartis; Pfizer; PharmaMar |
Research Funding - Bayer; Novartis; PharmaMar |
Travel, Accommodations, Expenses - PharmaMar |
| |
|
|
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
|